- Home
- PODC vs AARD Comparison
PODC vs AARD Comparison
Compare PODC & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PODC | AARD |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.1M | 107.7M |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PODC | AARD |
|---|---|---|
| Price | $2.31 | $5.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $5.67 | ★ $11.11 |
| AVG Volume (30 Days) | 65.8K | ★ 110.1K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.43 | N/A |
| Revenue Next Year | $18.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $3.35 |
| 52 Week High | $5.20 | $17.94 |
Technical Indicators
Market Signals| Indicator | PODC | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | N/A |
| Support Level | $2.03 | N/A |
| Resistance Level | $2.33 | N/A |
| Average True Range (ATR) | 0.26 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 55.56 | 0.00 |
Price Performance
Historical ComparisonAbout PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more. It generates all its revenue from United States. PodcastOne has built a distribution network reaching over a billion monthly impressions across all channels, including YouTube, Spotify, Apple Podcasts, and iHeartRadio.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.